Trial Profile
A Phase 2 Study of Transarterial Chemoperfusion Treatment With Cisplatin, Methotrexate and Gemcitabine in Patients With Unresectable Pleural Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Cisplatin; Methotrexate
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 24 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 10 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 05 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.